Licensed healthcare professionals evaluate each patient to determine eligibility and create personalized treatment plans focused on safe, sustainable weight loss and metabolic health
Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
In the Look Action for Health in Diabetes study, where overweight and obese patients with T2D were treated with intensive lifestyle intervention, patients had a mean weight loss of 8.6% after 1-year
Sosnik, A., Chiappetta, D
Its gentle yet effective blend nourishes the skin, helping improve overall texture, glow, and daily skincare results
Private and Self-Pay Arrangements Lead Treatment Access in South Korea In South Korea, the market is expected to remain dominated by private insurance and self-pay arrangements, which hold an 85% share in 2025